Company Profile

Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers. SL-401 consists of IL-3 recombinantly fused to a truncated diphtheria toxin payload. SL-701 is an immunotherapy designed to activate the immune system to attack tumors. SL-701 comprises various short synthetic peptides that correspond to epitopes of targets, including IL-13 receptor subunit alpha-2 (IL-13Ra2), ephrin type-A receptor 2 (EphA2) and survivin, present on brain cancer. SL-801 is an oral, small molecule that reversibly inhibits Exportin-1 (XPO1), also known as Chromosome Region Maintenance-1 (CRM-1), a nuclear transport protein.

Employees

Sector

Biotechnology & Medical Research

More about the company

14/06	Menarini Group and Stemline Therapeutics, Inc. Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis	CI
28/05	The Menarini Group and Stemline Therapeutics, Inc. Presents New Data From The Phase 1b/2 ELEVATE Study Of Elacestrant In Combination With Capivasertib In Patients With ER+, HER2- Metastatic Breast Cancer	CI
25/05	Menarini Group Announces New Data At the American Society of Clinical Oncology 2026 Annual Meeting	CI
09/12	Menarini Group and Stemline Therapeutics, Inc. Presents Elacestrant Phase 2 Combination Data in Patients with ER+, HER2- Metastatic Breast Cancer at the 2025 San Antonio Breast Cancer Symposium	CI
24/11	Menarini Group and Stemline Therapeutics, Inc. to Present New Data Related to ELZONRIS	CI
20/25/20	Menarini Group and Stemline Therapeutics Inc. Announce Collaboration with VisualDx to Aid in Identifying People Who May Have Blastic Plasmacytoid Dendritic Cell Neoplasm	CI
12/24/12	Menarini Group Along with Stemline Therapeutics, Inc and Medsir Present the Phase III Study Adela	CI
11/23/11	Menarini Group Presents Initial Safety and Efficacy Data from Phase 1B/2 Elevate and Electra Combination Studies of Orserdu® (Elacestrant) in Patients with Er+, Her2- Metastatic Breast Cancer At the 2023 San Antonio Breast Cancer Symposium	CI
08/23/08	Menarini Group and Stemline Therapeutics, Inc. Presents New Progression-Free Survival Data from Emerald Clinical Study of Orserdu (Elacestrant) in Clinically Relevant Subgroups of Patients with Esr1 Mutations At Sabcs 2023	CI
21/23/21	The Menarini Group and Stemline Therapeutics, Inc. to Present New Data Related to ORSerDU	CI
30/23/30	Quantum Leap Healthcare Collaborative Initiates Landmark Phase 2 RECAST DCIS Platform Trial to Evaluate Alternative DCIS Treatments with Atossa Therapeutics, Havah Therapeutics, and the Menarini Group	CI
20/23/20	European Commission Approves Menarini Group?s ORSERDU (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation	CI
26/23/26	The Menarini Group and Stemline Therapeutics Announce Results from A New Analysis of the Pivotal EMERALD Clinical Study	CI

17/20/17	Stemline Therapeutics : The Menarini Group received the coveted XV Transatlantic Award from the American Chamber of Commerce in Italy	AQ
10/20/10	STEMLINE THERAPEUTICS INC : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
12/20/12	STEMLINE THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
05/20/05	Stemline Therapeutics : The Menarini Group signs the agreement for the acquisition of Stemline Therapeutics for a maximum consideration of $ 677 million	AQ
04/20/04	STEMLINE THERAPEUTICS INC : Entry into a Material Definitive Agreement, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	AQ

16/19/16	Dow Jones Industrial Average : Les valeurs à suivre à Wall Street
16/19/16	USA-Les valeurs à suivre à Wall Street (actualisé)

Manager	Title	Age	Since
Ivan Bergstein CEO	Chief Executive Officer	60	-
David Gionco DFI	Director of Finance/CFO	65	16/01/2014
Jeffrey Levitt CMP	Compliance Officer	-	01/04/2021

Date	Insider	Type	Main position	Quantity	% Market Cap.
10/20/10	Robert Francomano	Tender	Executive/Senior Manager	2,50,891	0.4778%
10/20/10	Alan Forman	Tender	Director	1,46,298	0.2786%
10/20/10	Mark Sard	Tender	Director	51,468	0.0980%

Stemline Therapeutics, Inc. Share Price

Stocks

US85858C1071

Biotechnology & Medical Research

Latest news : Stemline Therapeutics, Inc.

Press Releases: Stemline Therapeutics, Inc.

News in other languages: Stemline Therapeutics, Inc.

Managers and Directors: Stemline Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
STEMLINE THERAPEUTICS, INC.	-.--%	-.--%	-	-	57Cr
ARGENX SE	-0.71%	-0.29%	+56.45%	+107.18%	5.49TCr
WUXI APPTEC CO., LTD.	-1.22%	+2.25%	+43.78%	+38.45%	4.43TCr
BIONTECH SE	-0.17%	+5.06%	-14.53%	-19.25%	2.3TCr
INSMED INCORPORATED	-3.43%	-4.54%	-6.94%	+372.70%	2.11TCr
WUXI BIOLOGICS (CAYMAN) INC.	-2.91%	-1.18%	+7.21%	-36.53%	1.63TCr
GENMAB A/S	-2.38%	-3.38%	+5.53%	-41.88%	1.52TCr
EXELIXIS, INC.	-0.74%	-0.67%	+26.07%	+175.72%	1.33TCr
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+1.48%	+11.36%	+22.59%	-	1.25TCr
PHARMAESSENTIA CORPORATION	+4.10%	+7.02%	+104.41%	+226.33%	1.12TCr
Average	-0.55%	+2.67%	+27.18%	+102.84%	2.35TCr
Weighted average by Cap.	-0.89%	+2.01%	+30.98%	+93.64%